Alkermes二季度收入增长但GAAP盈利与EBITDA指引受Avadel收购费用压制

Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
Introduction & Market Context
Alkermes plc (NASDAQ:ALKS) presented second-quarter 2026 financial results on July 28, 2026, revealing a complex picture of robust revenue growth tempered by significant profitability pressures stemming from its February acquisition of Avadel Pharmaceuticals. The pharmaceutical company’s shares traded at $51.43, down 2.47% from the previous close of $52.73, as investors weighed strong commercial momentum against acquisition-related headwinds.
The presentation highlighted total revenue of $496.0 million for the quarter, representing 27% year-over-year growth from $390.7 million in Q2 2025. However, GAAP net income collapsed to just $0.5 million from $87.1 million in the prior-year period, while GAAP earnings per share fell to $0.00 from $0.52.
Financial Performance Highlights
As shown in the following comparison of key financial metrics, Alkermes delivered substantial revenue growth in Q2 2026 while experiencing a sharp decline in GAAP profitability:
The dramatic divergence between revenue growth and bottom-line performance reflects the integration of Avadel, which closed on February 12, 2026. The acquisition brought LUMRYZ, a sodium oxybate treatment for narcolepsy, into Alkermes’ portfolio but also introduced significant non-cash charges including inventory fair value step-up ($105 million expensed in 2026) and intellectual property amortization ($1.8 billion over 14 years).
The company’s profitability metrics tell a more nuanced story when examining both GAAP and non-GAAP measures:
While GAAP net income fell to near-breakeven and EBITDA declined 52% to $49.0 million from $101.6 million, Adjusted EBITDA grew 10% to $139.2 million from $126.5 million. This gap illustrates the substantial impact of acquisition-related charges, share-based compensation ($31.3 million), acquisition costs ($32.5 million), and changes in fair value of contingent consideration ($26.4 million).
Product Portfolio Analysis
The company’s proprietary product portfolio demonstrated strong commercial execution, with total proprietary net sales reaching $411.7 million, up 34% year-over-year from $307.2 million. The detailed revenue breakdown reveals the contribution of each franchise:
VIVITROL, Alkermes’ extended-release injectable medication for alcohol and opioid dependence, generated $124.5 million in Q2 2026 compared to $121.7 million in the prior-year period, representing modest but steady growth. The following chart illustrates VIVITROL’s quarterly sales trajectory and full-year outlook:
ARISTADA, the company’s long-acting injectable antipsychotic, posted $96.7 million in net sales versus $101.3 million in Q2 2025, reflecting a slight year-over-year decline in a competitive market. The quarterly performance trend shows:
LYBALVI, an oral atypical antipsychotic combining olanzapine and samidorphan, delivered $94.0 million in net sales with gross-to-net deductions of approximately 36%. This represented 12% year-over-year growth from $84.3 million, driven by expanded access to more than 80% of insured lives. The product’s sales momentum is illustrated below:
LUMRYZ, the newly acquired narcolepsy treatment, contributed $96.6 million in Q2 2026 net sales, marking its first full quarter under Alkermes ownership. The stacked bar chart demonstrates the transition from Avadel to Alkermes and the product’s growth trajectory:
Revised Guidance & Outlook
Alkermes updated its full-year 2026 financial expectations, revising several key metrics downward due to acquisition-related impacts. The comprehensive comparison of previous and updated guidance reveals the extent of these adjustments:
The most significant changes include:
- GAAP Net Loss widened from ($70M) - ($90M) to ($95M) - ($115M)
- EBITDA reduced from $105M - $135M to $75M - $95M
- New line item for change in fair value of contingent consideration of approximately $25M
The contingent consideration adjustment of $26.4 million resulted from positive phase 3 study results for LUMRYZ in idiopathic hypersomnia, increasing the probability of milestone payments to former Avadel shareholders.
Product-level guidance remained unchanged, with expected full-year 2026 net sales of:
- VIVITROL: $460M - $480M
- LYBALVI: $380M - $400M
- ARISTADA: $365M - $385M
- LUMRYZ: $315M - $335M (representing the period from February 12 through December 31, 2026)
The company maintained its Adjusted EBITDA guidance range of $375M - $405M, signaling confidence in underlying operational performance despite GAAP accounting pressures.
Profitability Analysis: GAAP vs Non-GAAP Reconciliation
Understanding the gap between GAAP and non-GAAP metrics is essential for assessing Alkermes’ true operational performance. The detailed reconciliation for the three months ended June 30, 2026, breaks down the adjustments:
The reconciliation reveals that the company’s core operating performance remained solid, with Adjusted EBITDA of $139.2 million exceeding the prior year’s $126.5 million. However, acquisition-related costs ($32.5 million), changes in contingent consideration fair value ($26.4 million), and amortization of acquired intangible assets ($22.6 million) combined with increased interest expense ($25.9 million) to compress GAAP profitability.
For the full year 2026, the company’s projected reconciliation shows similar dynamics, with a projected GAAP net loss of $105 million (midpoint) transforming into projected Adjusted EBITDA of $390 million after excluding $125 million in share-based compensation, $155 million in acquisition costs, and $25 million in contingent consideration changes.
Strategic Implications
The presentation underscores Alkermes’ strategic bet on building a diversified neuroscience portfolio spanning addiction, psychiatry, and sleep medicine. The Avadel acquisition significantly expands the company’s presence in sleep disorders and provides a platform for advancing its orexin receptor agonist pipeline, which management views as a potential growth driver across multiple indications including ADHD, fatigue, and various sleep disorders.
With approximately $690 million in cash and investments at quarter-end, Alkermes maintains financial flexibility to fund continued pipeline development while absorbing the near-term profitability impact of the acquisition. The company’s gross profit margin of 87.45% over the last twelve months demonstrates strong product-level economics, even as bottom-line profitability remains pressured by acquisition integration costs and non-cash charges.
The revised guidance reflects management’s realistic assessment of the acquisition’s financial impact while maintaining confidence in commercial execution across all four proprietary franchises. Investors will be watching for continued LUMRYZ integration progress, LYBALVI access expansion, and advancement of the orexin pipeline, with key data readouts expected in the second half of 2026.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.